Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1

Stefano Giannetti, Quintino Giorgio D'Alessandris, Simone Pacioni, Maurizio Martini, Luigi Maria Larocca, Roberto Pallini, Maria Laura Falchetti, Mariachiara Buccarelli, Valentina Lulli, Eliza Vakana, Louis Stancato, Lucia Ricci-Vitiani

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

9 Citazioni (Scopus)


Bevacizumab, a VEGF-targeting monoclonal antibody, may trigger an infiltrative growth pattern in glioblastoma. We investigated this pattern using both a human specimen and rat models. In the human specimen, a substantial fraction of infiltrating tumor cells were located along perivascular spaces in close relationship with endothelial cells. Brain xenografts of U87MG cells treated with bevacizumab were smaller than controls (p = 0.0055; Student t-test), however, bands of tumor cells spread through the brain farther than controls (p < 0.001; Student t-test). Infiltrating tumor Cells exhibited tropism for vascular structures and propensity to form tubules and niches with endothelial cells. Molecularly, bevacizumab triggered an epithelial to mesenchymal transition with over-expression of the receptor Plexin Domain Containing 1 (PLXDC1). These results were validated using brain xenografts of patient-derived glioma stem-like cells. Enforced expression of PLXDC1 in U87MG cells promoted brain infiltration along perivascular spaces. Importantly, PLXDC1 inhibition prevented perivascular infiltration and significantly increased the survival of bevacizumab-treated rats. Our study indicates that bevacizumab-induced brain infiltration is driven by vascular endothelium and depends on PLXDC1 activation of tumor cells.
Lingua originaleEnglish
pagine (da-a)1331-1344
Numero di pagine14
RivistaInternational Journal of Cancer
Stato di pubblicazionePubblicato - 2019


  • Cancer Research
  • Oncology
  • PLXDC1
  • antiangiogenic therapy
  • bevacizumab
  • brain infiltration
  • glioblastoma


Entra nei temi di ricerca di 'Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1'. Insieme formano una fingerprint unica.

Cita questo